Canada Markets closed

Top Research Reports for Pfizer, Coca-Cola & VMware

Mark Vickery

Tuesday, June 4, 2019

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Pfizer (PFE), Coca-Cola (KO) and VMware (VMW). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Pfizer’s shares have underperformed the Zacks Large-Cap Pharmaceuticals industry year to date (-3.9% vs. -1.2%). Pfizer expects continued strong growth of key product franchises, including Ibrance, Eliquis, and Xeljanz in 2019. The Zacks analyst thinks loss of exclusivity on key drugs in the United States, mainly Lyrica and currency headwinds will significantly hurt sales in 2019.

Other top-line headwinds are weak sales in the sterile injectables portfolio, pricing pressure and rising competition. To offset the threat of generic competition, Pfizer is strengthening its pipeline as well as its oncology portfolio.

Pfizer looks well positioned to deliver several potential new breakthrough innovative medicines in the next five years, which can drive long-term growth. Bavencio is being considered as a key long-term growth driver. Biosimilars are also expected to contribute to growth in 2019.

(You can read the full research report on Pfizer here >>>).

Shares of Coca-Cola have increased +15.1% in the past year, outperforming the Zacks Soft Drinks Beverages industry which has gained +6.3% over the same period. The Zacks analyst thinks this is largely attributable to the effective execution of strategies aimed at evolving into a consumer-centric total beverage company.

This approach has bolstered its quarterly performances as is evident from a robust surprise trend. First-quarter 2019 marked its seventh positive earnings surprise in the last eight quarters and also the seventh straight sales beat. Ongoing productivity efforts and disciplined growth strategies along with robust performance across segments are aiding top and bottom lines.

Innovation and investment in core categories and brands has been the key focus area, which has led to the expansion of retail value share. Moreover, global re-franchising initiatives are expected to boost margins. However, currency rates are likely to significantly mar comparable revenues and operating income in the second quarter and the rest of 2019.

(You can read the full research report on Coca-Cola here >>>).

VMware’s shares have gained +44.4% year to date, outperforming the Zacks Software industry which is up +18.9% over the same period. VMware reported impressive first-quarter fiscal 2020 results. Both earnings and revenues increased on a year-over-year basis. Strong top-line growth was primarily driven by robust performance from NSX, VeloCloud and vSAN product lines.

The Zacks analyst thinks VMware’s dominance in software-defined data center (SDDC) and its expanding customer base in cloud driven by partnerships with the likes of IBM and AWS are major positives. Nevertheless, growth in license bookings has been muted for the last few quarters, owing to customer delays and macro-economic weakness in some key regions. Moreover, VMware’s margins are expected to remain under pressure due to heavy spending. Intensifying competition is also a concern.

(You can read the full research report on VMware here >>>).

Other noteworthy reports we are featuring today include Accenture (ACE), NIKE (NKE) and AIG (AIG).

Today's Best Stocks from Zacks

Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.

This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.

See their latest picks free >>

Mark Vickery
Senior Editor

Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>

Today's Must Read

Pfizer (PFE) to Launch New Drugs Amid Generic Headwinds


Investment, Innovation Power Coca-Cola's (KO) Growth


Portfolio Strength, Expanding Partner Base Aid VMware (VMW)


Featured Reports

Target's (TGT) Omnichannel & Store Expansion to Boost Sales

Per the Zacks analyst, Target's focus on enhancing omni-channel capacities, remodeling stores and expanding same-day delivery options are likely to fuel top-line growth.

CLARCOR Buyout Aids Parker-Hannifin (PH), High Costs Ail

Per the Zacks analyst, Parker-Hannifin's revamped "Win Strategy" along with the CLARCOR buyout should boost its growth prospects.

Palo Alto (PANW) Rides on Acquisitions and Partnerships

Per the Zacks analyst, Palo Alto's acquisitions, such as RedLock and Demisto, are widening its portfolio, thus boosting top line.

Marvell (MRVL) Rides On Solid Product Portfolio, Acquisitions

Per the Zacks analyst, Marvell is gaining from high demand for its OCTEON processors, Ethernet switch and PHY products.

High Demand for 5G Design & Test Solutions Aids Keysight (KEYS)

Per the Zacks analyst, robust adoption on account of high demand for 5G design and test solutions primarily from telecom vendors, and strong pipeline for new business bookings are key catalysts.

Focus on Renewables Aids AES Corp. (AES), Regulations Hurt

Per the Zacks analyst, AES Corp.'s focus on renewables should boost growth led by rapid expansion of renewable overseas footprint.

Blueprint Medicines (BPMC) Eyes Avapritinib NDA for GIST

Per the Zacks analyst, Blueprint Medicines targets the NDA for avapritinib to treat PDGFRA Exon 18 mutant GIST and the fourth-line GIST.

New Upgrades

Acquisitions, Divestitures, Cost Control Efforts To Aid AIG

Per the Zacks analyst, divestitures have released funds which can be invested in core areas. Buyouts of Validus and others should help business expansion. Cost control efforts should aid margins.

Cost Control, Solid Capital Base Boost Franklin (BEN)

Per the Zacks analyst, Franklin's efforts to drive operational efficiency remain encouraging. It also continues to benefit from a strong capital position and diversification.

Strong Demand & Cost Cuts Aid International Flavors (IFF)

Per the Zacks analyst, International Flavors is benefiting from increasing global demand for consumer products containing flavors and fragrances, the Frutarom acquisition and cost cutting efforts.

New Downgrades

Higher SG&A Expenses to Weigh on NIKE's (NKE) Margins

Per the Zacks analyst, higher SG&A expenses due to increased operating overheads and demand creation expenses have been hurting NIKE's margins. These headwinds are likely to persist in fiscal 2019.

Accenture (ACN) Hurt by Pricing Pressure, Integration Risk

The Zacks analyst believes that pricing pressure due to stiff competition weighs on Accenture's bottom line. Frequent acquisitions add to integration risks.

CommScope (COMM) Plagued by Tariff War & Margin Woes

Per the Zacks analyst, simmering U.S.-China trade tensions are likely to hurt CommScope's growth prospects. Higher operating expenses are also likely to prove detrimental to margins.


undefined undefined
 
VMware, Inc. (VMW) : Free Stock Analysis Report
 
Pfizer Inc. (PFE) : Free Stock Analysis Report
 
NIKE, Inc. (NKE) : Free Stock Analysis Report
 
Coca-Cola Company (The) (KO) : Free Stock Analysis Report
 
American International Group, Inc. (AIG) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research